VIVUS (VVUS) Sinks on Conference Call; 30% of Qsymia Scipts Abandoned Due to Cash Outlay
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Wall Street stocks fall as weak GDP growth spreads rate-cut gloom
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Alphabet (GOOGL) soars 16% on Q1 results beat, first-ever dividend
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil settles higher as weak U.S. economic growth offset by supply concerns
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
Jefferies Slashes Numbers on Vivus (VVUS) on Slow Qsymia Uptake; Sees Another 45% Downside
November 7, 2012 12:33 PM ESTJefferies slashed its price target on Underperform-rated Vivus (NASDAQ: VVUS) Wednesday from $13 to $6 to reflect the slow Qsymia uptake.
VVUS disclosed that there have been 5,560 Qsymia prescriptions shipped through October 26. This is 30% below the IMS data (7,865 after applying adjustment factors) and SHA (formerly Wolters Kluwer) data... More
Needham & Company Cuts Numbers on VIVUS Inc. (VVUS) on Slower Qsymia Launch, Keeps Buy on Blockbuster Potential
November 6, 2012 3:02 PM ESTNeedham & Company lowered estimates and its price target on Vivus (NASDAQ: VVUS) from $32 to $20 following Q3 results, but kept its Buy rating.
Qsymia was launched in the U.S. in mid-Sept. and were $41,000 during the abbreviated quarter. The company noted 3504 unique patients filled... More
VIVUS (VVUS) Sell Off Overdone; Wells Says All Drugs Have Abandonment, Co-Pay Issues
November 6, 2012 12:20 PM ESTVIVUS, Inc. (Nasdaq: VVUS) continues to trade over 20 percent lower following the pharma's conference call and third-quarter results today. But, not everyone's convinced that the drop is warranted.
Though the firm still has some concerns, Wells Fargo analyst Michael Tong sees today's... More
VIVUS (VVUS) Ticks Lower; Wider Q3 Loss Attributed to Qsymia Launch, Expansion (ARNA) (OREX)
November 6, 2012 8:56 AM ESTVIVUS, Inc. (Nasdaq: VVUS) is trading higher in early action following third-quarter results issued earlier.
Though revs were just $41 million, VIVUS noted that, "[g]iven the lack of history in selling Qsymia, VIVUS will recognize revenue on the sell-through method, that is, revenue is recognized as prescriptions... More
VIVUS, Inc. (VVUS) Posts Wider than Expected Q3 Loss of 40c/Share
November 6, 2012 8:16 AM ESTVIVUS, Inc. (Nasdaq: VVUS) reported Q3 EPS of ($0.40), $0.09 worse than the analyst estimate of ($0.31). Revenue for the quarter came in at $41 thousand versus the consensus estimate of $310 thousand.
For earnings history and earnings-related data on Vivus, Inc. (VVUS) click here.... More
